PF-Atlas › Clinical Trials › FIBRONEER-IPF

Nerandomilast PDE4B Inhibitor — FIBRONEER-IPF Phase III

Nerandomilast · PDE4B Inhibition · Phase 3

Registry ID
FIBRONEER-IPF
Phase
Phase 3
Status
Completed
Drug / intervention
Nerandomilast (Jascayd)
Mechanism
PDE4B Inhibition
Sponsor
Boehringer Ingelheim
Start
2020-09

About this trial

Nerandomilast is evaluated in FIBRONEER-IPF, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Boehringer Ingelheim, targeting pde4b inhibition. Current status: Completed.

View FIBRONEER-IPF on ClinicalTrials.gov →

Explore related

Nerandomilast / Jascayd — Treatment profileAll Nerandomilast trialsPDE4B Inhibition mechanismAll IPF trials

Related trials

Nerandomilast — FIBRONEER-ILDNerandomilast — NCT07201922Nerandomilast — NCT07366034Nerandomilast — NCT06238622Nerandomilast — NCT07540988Nerandomilast — NCT06806592
Medical disclaimer. This page summarizes public trial data for FIBRONEER-IPF for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.